Repligen Corporation reported its fourth quarter and full year 2024 financial results, achieving an adjusted earnings per share (EPS) of 44 cents, surpassing the consensus estimate of 41 cents. The company also reported sales of $167.55 million. CEO expressed optimism regarding the company's outlook for 2025, highlighting a return to growth in the overall bioprocessing market and positive order momentum in the second half of the fiscal year. HC Wainwright & Co. reiterated a Buy rating on Repligen, maintaining a price target of $180.